Back to Crohns Disease And Colitis
NCT05242471
NCT05242471
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with Crohn's disease for at least 3 months before the start of the trial
- Your Crohn's disease has been confirmed as moderate to severe (confirm with trial site for how this is measured)
Who may not be able to join:
- The exclusion criteria were not fully provided in the source, so please confirm all requirements directly with the trial site
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Active, Not Recruiting
Phase
Phase 2
Sponsor
Janssen Research & Development, LLC
Registry
clinicaltrials_gov
Start date
22 July 2022
Est. completion
23 May 2025
Where this trial is recruiting
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇳 China
🇭🇷 Croatia
🇨🇿 Czechia
🇩🇰 Denmark
🇪🇪 Estonia
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇳 India
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇯🇴 Jordan
🇲🇾 Malaysia
🇳🇱 Netherlands
🇳🇿 New Zealand
🇳🇴 Norway
🇵🇱 Poland
🇵🇹 Portugal
🇸🇬 Singapore
🇸🇮 Slovenia
🇿🇦 South Africa
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
🇹🇼 Taiwan
🇬🇧 United Kingdom
🇺🇸 United States
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants with Clinical Remission at Week 48; Percentage of Participants with Endoscopic Response at Week 48
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.